What benefits are associated with Mod GRF 1-29?

Mod GRF 1-29 is studied for: pituitary GHRH receptor agonism — pulsatile GH stimulation, improved proteolytic stability vs native GHRH 1-29, synergistic GH release when combined with GHRPs (ipamorelin, GHRP-6), ~30 min half-life — requires dosing at each session vs CJC-1295 with DAC (weekly). This reflects the research literature catalogued on PeptideBase — educational only, not medical advice.

Educational use only — not medical advice

Research library

Mod GRF 1-29 benefits

From the PeptideBase research library. Educational only — not medical advice.

Studied effects

pituitary GHRH receptor agonism — pulsatile GH stimulation
improved proteolytic stability vs native GHRH 1-29
synergistic GH release when combined with GHRPs (ipamorelin, GHRP-6)
~30 min half-life — requires dosing at each session vs CJC-1295 with DAC (weekly)

Mechanism

Modified GHRH analog; binds GHRH receptors with improved stability to produce physiological GH pulses when combined with a GHRP